Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Source :

• Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-04.

English descriptors

• KwdEn :
  • Abatacept, Active disease, Adacta trial, Adalimumab, Adalimumab monotherapy, Adult onset disease, Adult patients, Adverse event, Adverse events, Advisory board meetings, Advisory boards, Aletaha, American college, Anaphylactic reactions, Ankylosing spondylitis, Antirheumatic, Antirheumatic drugs, Antiviral agents, Arthritis, Arthritis care, Arthritis rheum, Available data, Axial spondyloarthritis, Baseline, Biologic agents, Biological agents, Biological antirheumatic drugs, Cardiovascular risk, Chronic hepatitis, Clin, Clinical disease activity index, Clinical immunology, Clinical practice, Clinical remission, Clinical superiority, Clinical trial, Clinical trial data, Clinical trials, Combination therapy, Composite measure, Consensus, Consensus statement, Consensus statement table, Consensus statements, Consulting fees research grants, Disease activity, Disease activity score, Dmards, Dose escalation, Dose increase, Eular, Eular recommendations, Expert advice, Expert opinion, Gastrointestinal perforations, Giant cell arteritis, Glucocorticoid therapy, Grant support, Health professionals, Hepatitis, Higher dose, Human receptor, Humanized receptor antibody, Inadequate response, Inadequate responses, Individual classes, Infusion, Inhibition, Inhibitor, Internal medicine, International study, Intravenous infusion, Joint counts, Joint damage, Juvenile idiopathic arthritis, Latent tuberculosis, Lower dose, Medical university, Methotrexate, Monoclonal antibody, Monotherapy, More information, Multicentric castleman disease, Nishimoto, Online, Online supplement, Other biologicals, Other compounds, Other diseases, Other dmards, Other indications, Other inhibitors, Other sdmards, Pathway, Pathway inhibition, Perforation, Polymyalgia rheumatica, Possible contraindications, Psoriatic arthritis, Randomised, Randomized, Receptor, Receptor antibody, Receptor inhibition, Remission, Research grants, Response rates, Rheum, Rheumatic disease, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatol, Rheumatology, Risk factors, Rituximab, Roche, Safety aspects, Sdmards, Serious infections, Several case reports, Significant differences, Smolen, Synthetic disease, Systematic literature review, Systematic review, Systemic lupus erythematosus, Systemic sclerosis, Task force, Therapy, Tocilizumab, Tocilizumab monotherapy, Treatment option, Treatment target, Tumor necrosis factor, Tumour necrosis factor, Virus infection, Washout period.
• Teeft :
  • Abatacept, Active disease, Adacta trial, Adalimumab, Adalimumab monotherapy, Adult onset disease, Adult patients, Adverse event, Adverse events, Advisory board meetings, Advisory boards, Aletaha, American college, Anaphylactic reactions, Ankylosing spondylitis, Antirheumatic, Antirheumatic drugs, Antiviral agents, Arthritis, Arthritis care, Arthritis rheum, Available data, Axial spondyloarthritis, Baseline, Biologic agents, Biological agents, Biological antirheumatic drugs, Cardiovascular risk, Chronic hepatitis, Clin, Clinical disease activity index, Clinical immunology, Clinical practice, Clinical remission, Clinical superiority, Clinical trial, Clinical trial data, Clinical trials, Combination therapy, Composite measure, Consensus, Consensus statement, Consensus statement table, Consensus statements, Consulting fees research grants, Disease activity, Disease activity score, Dmards, Dose escalation, Dose increase, Eular, Eular recommendations, Expert advice, Expert opinion, Gastrointestinal perforations, Giant cell arteritis, Glucocorticoid therapy, Grant support, Health professionals, Hepatitis, Higher dose, Human receptor, Humanized receptor antibody, Inadequate response, Inadequate responses, Individual classes, Infusion, Inhibition, Inhibitor, Internal medicine, International study, Intravenous infusion, Joint counts, Joint damage, Juvenile idiopathic arthritis, Latent tuberculosis, Lower dose, Medical university, Methotrexate, Monoclonal antibody, Monotherapy, More information, Multicentric castleman disease, Nishimoto, Online, Online supplement, Other biologicals, Other compounds, Other diseases, Other dmards, Other indications, Other inhibitors, Other sdmards, Pathway, Pathway inhibition, Perforation, Polymyalgia rheumatica, Possible contraindications, Psoriatic arthritis, Randomised, Randomized, Receptor, Receptor antibody, Receptor inhibition, Remission, Research grants, Response rates, Rheum, Rheumatic disease, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatol, Rheumatology, Risk factors, Rituximab, Roche, Safety aspects, Sdmards, Serious infections, Several case reports, Significant differences, Smolen, Synthetic disease, Systematic literature review, Systematic review, Systemic lupus erythematosus, Systemic sclerosis, Task force, Therapy, Tocilizumab, Tocilizumab monotherapy, Treatment option, Treatment target, Tumor necrosis factor, Tumour necrosis factor, Virus infection, Washout period.

Abstract

• https://api.istex.fr/document/B7684EF8379AD6695DCF92C88BB2940E8C72BDC5/fulltext/pdf
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595138

Affiliations:

• Allemagne, Australie, Autriche, Danemark, Espagne, France, Italie, Japon, Norvège, Pays-Bas, Royaume-Uni, République tchèque, Suisse, États-Unis
• Angleterre, Berlin, Bohême centrale, Communauté de Madrid, Grand Londres, Hollande-Méridionale, Hollande-Septentrionale, Hovedstaden, Languedoc-Roussillon, Latium, Maryland, Occitanie (région administrative), Oregon, Vienne (Autriche), Écosse, État de New York, Île-de-France, Østlandet
• Amsterdam, Berlin, Copenhague, Glasgow, Leyde, Londres, Madrid, Montpellier, Oslo, Paris, Prague, Rome, Vienne (Autriche)
• Université de Glasgow

Links toward previous steps (curation, corpus...)

• to stream Istex, to step Corpus: 002241
• to stream Istex, to step Curation: 002241
• to stream Istex, to step Checkpoint: 000212
• to stream Pmc, to step Corpus: 002254
• to stream Pmc, to step Curation: 002104
• to stream Pmc, to step Checkpoint: 001F97
• to stream Ncbi, to step Merge: 001040
• to stream Ncbi, to step Curation: 001040
• to stream Ncbi, to step Checkpoint: 001040
• to stream Main, to step Merge: 004A26
• to stream Main, to step Curation: 004902

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004902 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004902 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:B7684EF8379AD6695DCF92C88BB2940E8C72BDC5
   |texte=   Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
}}

This area was generated with Dilib version V0.6.33. Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024